Metabolome and metaboproteome remodeling in nuclear reprogramming
暂无分享,去创建一个
D. K. Arrell | A. Terzic | C. Perez-Terzic | T. Nelson | Jelena Zlatkovic-Lindor | A. Martinez-Fernandez | Clifford D. L. Folmes | Timothy J. Nelson
[1] J. Menéndez,et al. The mitochondrial H+-ATP synthase and the lipogenic switch , 2013, Cell cycle.
[2] G. Daley,et al. Influence of Threonine Metabolism on S-Adenosylmethionine and Histone Methylation , 2013, Science.
[3] Jeroen Krijgsveld,et al. Highly coordinated proteome dynamics during reprogramming of somatic cells to pluripotency. , 2012, Cell reports.
[4] G. Daley,et al. Metabolic regulation in pluripotent stem cells during reprogramming and self-renewal. , 2012, Cell stem cell.
[5] A. Terzic,et al. Metabolic plasticity in stem cell homeostasis and differentiation. , 2012, Cell stem cell.
[6] Andre Terzic,et al. Systems proteomics for translational network medicine. , 2012, Circulation. Cardiovascular genetics.
[7] J. Menéndez,et al. Mitochondrial fusion by pharmacological manipulation impedes somatic cell reprogramming to pluripotency: New insight into the role of mitophagy in cell stemness , 2012, Aging.
[8] M. Teitell,et al. Measuring energy metabolism in cultured cells, including human pluripotent stem cells and differentiated cells , 2012, Nature Protocols.
[9] L. Studer,et al. The expanding role of miR-302–367 in pluripotency and reprogramming , 2012, Cell cycle.
[10] Andre Terzic,et al. Energy metabolism plasticity enables stemness programs , 2012, Annals of the New York Academy of Sciences.
[11] G. Siuzdak,et al. Innovation: Metabolomics: the apogee of the omics trilogy , 2012, Nature Reviews Molecular Cell Biology.
[12] George Q. Daley,et al. Reprogramming Cellular Identity for Regenerative Medicine , 2012, Cell.
[13] C. López-Otín,et al. Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells , 2012, Cell cycle.
[14] L. Cantley,et al. Human pluripotent stem cells decouple respiration from energy production , 2011, The EMBO journal.
[15] Laurent Vergnes,et al. UCP2 regulates energy metabolism and differentiation potential of human pluripotent stem cells , 2011, The EMBO journal.
[16] A. Terzic,et al. Energy metabolism in nuclear reprogramming. , 2011, Biomarkers in medicine.
[17] Juan Carlos Izpisua Belmonte,et al. The metabolome of induced pluripotent stem cells reveals metabolic changes occurring in somatic cell reprogramming , 2011, Cell Research.
[18] J. Menéndez,et al. mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: A roadmap from energy metabolism to stem cell renewal and aging , 2011, Cell cycle.
[19] C. Sander,et al. Genome-wide identification of microRNA targets in human ES cells reveals a role for miR-302 in modulating BMP response. , 2011, Genes & development.
[20] Hans Lehrach,et al. Human Induced Pluripotent Stem Cells Harbor Homoplasmic and Heteroplasmic Mitochondrial DNA Mutations While Maintaining Human Embryonic Stem Cell–like Metabolic Reprogramming , 2011, Stem cells.
[21] Andre Terzic,et al. Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. , 2011, Cell metabolism.
[22] J. I. Izpisúa Belmonte,et al. Anaerobicizing into pluripotency. , 2011, Cell metabolism.
[23] G. Schatten,et al. Energy Metabolism in Human Pluripotent Stem Cells and Their Differentiated Counterparts , 2011, PloS one.
[24] Michel Sadelain,et al. miR-371-3 expression predicts neural differentiation propensity in human pluripotent stem cells. , 2011, Cell stem cell.
[25] J. Ellis,et al. iPSC Technology: Platform for Drug Discovery , 2011, Clinical pharmacology and therapeutics.
[26] Robert L. Judson,et al. Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells , 2011, Nature Biotechnology.
[27] I. Sancho-Martinez,et al. Disease Correction the iPSC Way: Advances in iPSC‐Based Therapy , 2011, Clinical pharmacology and therapeutics.
[28] Timothy J. Nelson,et al. Induced Pluripotent Stem Cells: An Emerging Theranostics Platform , 2011, Clinical pharmacology and therapeutics.
[29] S. Yamanaka,et al. The Use of Induced Pluripotent Stem Cells in Drug Development , 2011, Clinical pharmacology and therapeutics.
[30] A. Tsirigos,et al. Ketones and lactate increase cancer cell “stemness,” driving recurrence, metastasis and poor clinical outcome in breast cancer , 2011, Cell cycle.
[31] J. Adjaye,et al. Modulation of mitochondrial biogenesis and bioenergetic metabolism upon in vitro and in vivo differentiation of human ES and iPS cells. , 2010, The International journal of developmental biology.
[32] Sheng Ding,et al. Reprogramming of human primary somatic cells by OCT4 and chemical compounds. , 2010, Cell stem cell.
[33] Andre Terzic,et al. Induced pluripotent stem cells: developmental biology to regenerative medicine , 2010, Nature Reviews Cardiology.
[34] Mark Ellisman,et al. Mitochondrial Rejuvenation After Induced Pluripotency , 2010, PloS one.
[35] Alfredo Quiñones-Hinojosa,et al. Oxygen in stem cell biology: a critical component of the stem cell niche. , 2010, Cell stem cell.
[36] D. K. Arrell,et al. ATP‐Sensitive K+ Channel‐Deficient Dilated Cardiomyopathy Proteome Remodeled by Embryonic Stem Cell Therapy , 2010, Stem cells.
[37] H. Schöler,et al. Induced pluripotent stem cells at nanoscale. , 2010, Stem cells and development.
[38] M. Stojkovic,et al. Human Induced Pluripotent Stem Cell Lines Show Stress Defense Mechanisms and Mitochondrial Regulation Similar to Those of Human Embryonic Stem Cells , 2010, Stem cells.
[39] Hans Lehrach,et al. The Senescence‐Related Mitochondrial/Oxidative Stress Pathway is Repressed in Human Induced Pluripotent Stem Cells , 2010, Stem cells.
[40] C. Pereira,et al. Senescence impairs successful reprogramming to pluripotent stem cells. , 2009, Genes & development.
[41] T. Ichisaka,et al. Hypoxia enhances the generation of induced pluripotent stem cells. , 2009, Cell stem cell.
[42] T. Ichisaka,et al. Suppression of induced pluripotent stem cell generation by the p53–p21 pathway , 2009, Nature.
[43] Manuel Serrano,et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity , 2009, Nature.
[44] M. Blasco,et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming , 2009, Nature.
[45] Timothy J. Nelson,et al. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. , 2009, Circulation.
[46] G. Stein,et al. Pluripotency: Toward a gold standard for human ES and iPS cells , 2009, Journal of cellular physiology.
[47] Peter W Zandstra,et al. Alternative induced pluripotent stem cell characterization criteria for in vitro applications. , 2009, Cell stem cell.
[48] Shinya Yamanaka,et al. Broader implications of defining standards for the pluripotency of iPSCs. , 2009, Cell stem cell.
[49] L. Fink,et al. Phenotypic correction of murine hemophilia A using an iPS cell-based therapy , 2009, Proceedings of the National Academy of Sciences.
[50] K. Hochedlinger,et al. Guidelines and techniques for the generation of induced pluripotent stem cells. , 2008, Cell stem cell.
[51] Ryan B. Huang,et al. Effects of oxygen on mouse embryonic stem cell growth, phenotype retention, and cellular energetics. , 2008, Biotechnology and bioengineering.
[52] R. Roberts,et al. Identification of oxygen-sensitive transcriptional programs in human embryonic stem cells. , 2008, Stem cells and development.
[53] R. Jaenisch,et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease , 2008, Proceedings of the National Academy of Sciences.
[54] O. Lee,et al. Coordinated Changes of Mitochondrial Biogenesis and Antioxidant Enzymes During Osteogenic Differentiation of Human Mesenchymal Stem Cells , 2008, Stem cells.
[55] D. K. Arrell,et al. Cardioinductive Network Guiding Stem Cell Differentiation Revealed by Proteomic Cartography of Tumor Necrosis Factor α‐Primed Endodermal Secretome , 2008, Stem cells.
[56] Fidel Ramírez,et al. Computing topological parameters of biological networks , 2008, Bioinform..
[57] Marius Wernig,et al. Treatment of Sickle Cell Anemia Mouse Model with iPS Cells Generated from Autologous Skin , 2007, Science.
[58] B. Bavister,et al. Mitochondria in stem cells. , 2007, Mitochondrion.
[59] D. K. Arrell,et al. Cardiopoietic programming of embryonic stem cells for tumor-free heart repair , 2007, The Journal of experimental medicine.
[60] Andre Terzic,et al. Mitochondrial oxidative metabolism is required for the cardiac differentiation of stem cells , 2007, Nature Clinical Practice Cardiovascular Medicine.
[61] Eyal Gottlieb,et al. TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis , 2006, Cell.
[62] A. Tabilio,et al. Characterization of Mitochondrial and Extra-mitochondrial Oxygen Consuming Reactions in Human Hematopoietic Stem Cells , 2005, Journal of Biological Chemistry.
[63] R. Roberts,et al. Low O2 tensions and the prevention of differentiation of hES cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[64] R. Albert,et al. The large-scale organization of metabolic networks , 2000, Nature.
[65] D. N. Perkins,et al. Probability‐based protein identification by searching sequence databases using mass spectrometry data , 1999, Electrophoresis.
[66] J. Lindon,et al. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.
[67] Albert,et al. Emergence of scaling in random networks , 1999, Science.
[68] O. Fiehn. Metabolomics – the link between genotypes and phenotypes , 2004, Plant Molecular Biology.